April 19, 2022
JCR Pharmaceuticals and Teijin have decided to wind up their codevelopment and licensing pact for JTR-161, an allogeneic regenerative medicine product containing dental pulp stem cells (DPCs), for the treatment of acute cerebral infarctions (strokes) in Japan, they said on...read more